Leukotriene B4 (LTB4) is a potent pro-inflammatory eicosanoid derived from arachidonic acid via the 5-LOX pathway, primarily synthesized by neutrophils, macrophages, and mast cells within seconds to minutes of inflammatory stimulation. It functions as one of the most powerful chemoattractants known for leukocytes (especially neutrophils), binding to BLT1 and BLT2 receptors to trigger chemotaxis, adhesion, degranulation, and respiratory burst. LTB4 represents a critical amplification node in acute inflammation, but also drives pathology when its production remains unchecked in chronic inflammation.
Imagine LTB4 as a smoke signal sent up from a battlefield. When immune cells (especially neutrophils) encounter trouble—bacteria, tissue damage, inflammatory triggers—they release LTB4 into the surrounding tissue like thick black smoke. This smoke rises and spreads rapidly through the neighborhood, and every patrolling neutrophil within range sees it and sprints toward the source. The smoke doesn't just attract reinforcements; it also arms them—neutrophils arriving at the scene are primed to degranulate (release their weapons), generate toxic oxygen radicals (light molecular fires), and stick tightly to blood vessel walls so they can cross into the battlefield.
The problem? If the smoke signal never stops, you get a permanent traffic jam of overactive, weapon-loaded soldiers piling into tissue that's already inflamed. In chronic conditions like asthma, rheumatoid arthritis, or inflammatory bowel disease, LTB4 becomes the smoke that never clears—a persistent alarm keeping inflammation locked in the "on" position. Contrast this with Specialized pro-resolving mediators (SPMs) like Resolvins—those are the "all clear" signals that tell the soldiers to stand down and go home. The switch from LTB4 production to SPM production is the difference between a controlled fire drill and a building burning indefinitely.
LTB4 biosynthesis begins with the release of arachidonic acid from membrane phospholipids by phospholipase A2 (PLA2), activated by inflammatory stimuli including cytokines, complement fragments (C5a), and pathogen-associated molecular patterns via TLR signaling.
Enzymatic cascade:
-
Arachidonic acid → 5-LOX + FLAP → 5-hydroperoxyeicosatetraenoic acid (5-HPETE)
- 5-LOX (5-lipoxygenase) is the rate-limiting enzyme, requiring 5-LOX-activating protein (FLAP) and Calcium for activity
- Primarily occurs in leukocytes (neutrophils, macrophages, mast cells, eosinophils)
-
5-HPETE → 5-LOX (LTA4 synthase activity) → Leukotriene A4 (LTA4)
- LTA4 is an unstable epoxide intermediate
-
LTA4 → LTA4 hydrolase → Leukotriene B4 (LTB4)
- This final step occurs in the cytosol
- Alternative pathway: LTA4 can be converted to cysteinyl leukotrienes (LTC4, LTD4, LTE4) by LTC4 synthase
Receptor signaling:
LTB4 binds to two G-protein coupled receptors:
-
BLT1 (high-affinity receptor, Kd ~1 nM) → Gαi/Gαq coupling → PLC activation → IP3 and DAG production → intracellular Calcium release + PKC activation → chemotaxis, adhesion molecule upregulation (CD11b/CD18), respiratory burst (NADPH oxidase activation → Reactive Oxygen Species generation), degranulation
-
BLT2 (low-affinity receptor, Kd ~20-100 nM) → weaker chemotactic signals, possible anti-inflammatory regulatory role in some contexts
Amplification loops:
LTB4 → BLT1 activation → NF-kB and ERK pathway activation → IL-8, TNF-α, IL-1β production → further PLA2 activation → more LTB4 synthesis (positive feedback)
Inactivation:
LTB4 undergoes rapid omega-oxidation by CYP4F enzymes (particularly CYP4F3A in neutrophils) → 20-hydroxy-LTB4 → 20-carboxy-LTB4 → excreted. Half-life: 5-15 minutes.
graph TD
A[Membrane Phospholipids] -->|PLA2| B[Arachidonic Acid]
B -->|"5-LOX + FLAP + Ca²⁺"| C[5-HPETE]
C -->|5-LOX| D[LTA4]
D -->|LTA4 Hydrolase| E[LTB4]
D -->|LTC4 Synthase| F[Cysteinyl Leukotrienes]
E -->|BLT1 receptor| G["Gαi/Gαq signaling"]
G --> H[PLC activation]
H --> I["IP3 + DAG"]
I --> J["Ca²⁺ mobilization"]
I --> K[PKC activation]
J --> L[Chemotaxis]
K --> M[Adhesion molecule expression]
K --> N[Degranulation]
K --> O[Respiratory burst - ROS]
G --> P["NF-κB + ERK activation"]
P --> Q["IL-8, TNF-α, IL-1β production"]
Q -->|Positive feedback| A
E -->|CYP4F3A| R[20-OH-LTB4]
R --> S[20-COOH-LTB4]
S --> T[Excretion]
Acute inflammation: LTB4 is essential for rapid neutrophil recruitment to sites of infection or injury, peaking within minutes and declining as Lipid mediator class switching occurs toward SPM production during normal resolution of inflammation. This is protective and necessary.
Chronic inflammatory disease: Persistent LTB4 production without class switching to SPMs drives tissue-destructive inflammation:
- Asthma: Sputum LTB4 levels correlate with disease severity (>200 pg/mL in severe asthma vs <50 pg/mL in controls); drives neutrophilic airway inflammation and bronchial hyperresponsiveness
- Rheumatoid arthritis: Synovial fluid LTB4 concentrations reach 5-15 nM (100-500x plasma levels), driving joint destruction and correlating with erosive disease
- Inflammatory bowel disease: Colonic mucosal LTB4 production is 3-10 fold elevated in active Crohn's and ulcerative colitis, perpetuating intestinal inflammation
- Atherosclerosis: LTB4 recruits leukocytes to vessel walls, promoting plaque formation and instability
cPNI metamodel connections:
- 5 plus 2 metamodel: LTB4 represents failure of resolution (metamodel 5—immune system selfishness). Chronic LTB4 signaling indicates stuck inflammatory programming, often coupled with metabolic dysfunction (metamodel 2—metabolic-dysfunction).
- Selfish Immune System: Persistent LTB4 production reflects an immune system prioritizing immediate threat response over tissue repair, draining metabolic resources (ATP, NADPH for respiratory burst) and creating chronic low-grade inflammation.
- Evolutionary mismatch: Modern Western diet high in Omega-3 ratio creates substrate excess (high arachidonic acid:EPA ratio) favoring LTB4 over less inflammatory leukotriene B5 (LTB5) from EPA.
Intervention implications:
- Omega-3 fatty acids (especially EPA 2-4 g/day): Competitively inhibits 5-LOX, reduces LTB4 by 20-40%, increases LTB5 (100-1000x weaker inflammatory potency)
- 5-LOX inhibitors (zileuton): Directly block LTB4 synthesis; clinical use limited by hepatotoxicity but demonstrates mechanism
- Specialized pro-resolving mediators (SPMs) supplementation: Resolvins, maresins, protectins actively counter-regulate BLT1 signaling and promote class switching
- Lifestyle factors: Exercise (acute LTB4 spike followed by enhanced SPM production), Heat therapy (modulates 5-LOX activity), stress reduction (cortisol modulates PLA2)
Biomarkers:
- Plasma LTB4: Normal <50 pg/mL; >100 pg/mL suggests active systemic inflammation
- Exhaled breath condensate LTB4: >10 pg/mL indicates airway inflammation
- Urinary LTB4 metabolites (20-COOH-LTB4): Reflects whole-body leukotriene production
- LTB4 is one of the most potent neutrophil chemoattractants ever identified (effective at nanomolar concentrations)
- Production occurs within 30 seconds to 5 minutes of inflammatory stimulus (extremely rapid response)
- Binds to BLT1 receptor with Kd ~1 nM (high affinity) and BLT2 with Kd ~20-100 nM (low affinity)
- Biological half-life of 5-15 minutes due to rapid omega-oxidation by CYP4F3A in neutrophils
- EPA and DHA compete with arachidonic acid for 5-LOX, producing LTB5 (100-1000 fold less potent than LTB4)
- LTB4 levels are 100-500 fold higher in inflammatory exudates (synovial fluid, sputum) than in plasma
- Omega-6 to omega-3 ratio >15:1 (typical Western diet) favors LTB4; ratio <4:1 (Mediterranean/ancestral) reduces it
- BLT1 knockout mice show impaired bacterial clearance but also reduced tissue damage in inflammatory models
- LTB4 stimulates NADPH oxidase producing superoxide (O₂⁻) at rates of 10-50 nmol/10⁶ neutrophils/min during respiratory burst
- Aspirin-triggered lipoxins (ATL) and resolvins directly antagonize BLT1 receptor signaling, initiating resolution
- arachidonic acid — Direct precursor fatty acid; dietary balance with omega-3s determines LTB4 production capacity
- 5-LOX — Rate-limiting enzyme converting arachidonic acid to LTA4; target for therapeutic inhibition
- phospholipase A2 — Liberates arachidonic acid from cell membranes; activated by inflammatory signals initiating LTB4 cascade
- neutrophils — Primary producers and most responsive targets of LTB4; undergo chemotaxis within seconds of exposure
- macrophages — Major LTB4 producers in chronic inflammation; drive tissue remodeling and fibrosis through sustained leukotriene release
- mast cells — Release preformed and de novo synthesized LTB4 during degranulation in allergic and inflammatory responses
- Specialized pro-resolving mediators (SPMs) — Counter-regulatory lipid mediators (resolvins, maresins, protectins) that antagonize LTB4 signaling and promote resolution
- Lipid mediator class switching — Critical transition from LTB4 dominance to SPM production marking shift from inflammation to resolution
- Resolvins — Directly inhibit BLT1 receptor and promote efferocytosis, actively resolving LTB4-driven inflammation
- Omega-3 fatty acids — EPA and DHA competitively inhibit 5-LOX reducing LTB4 while producing weak LTB5 and resolution-promoting SPMs
- EPA — Generates LTB5 (vastly weaker than LTB4) when processed by 5-LOX; clinical target ratio >3% in RBC membranes
- DHA — Substrate for D-series resolvins and protectins that counter-regulate LTB4 inflammatory effects
- inflammation — LTB4 is central amplification mediator recruiting and activating leukocytes in both acute protective and chronic pathological inflammation
- acute inflammation — LTB4 rapidly recruits neutrophils (minutes) for pathogen clearance; normal when followed by resolution
- chronic inflammation — Persistent LTB4 without class switching to SPMs drives tissue destruction in arthritis, IBD, asthma, atherosclerosis
- chemokines — LTB4 acts synergistically with IL-8, CXCL1, CXCL2 creating chemotactic gradients for neutrophil migration
- prostaglandin E2 — Parallel eicosanoid from COX-2 pathway; works with LTB4 driving pain, fever, vascular permeability
- COX-2 — Competes with 5-LOX for arachidonic acid substrate; COX-2 inhibition may shunt toward increased leukotriene production
- asthma — Sputum LTB4 >200 pg/mL in severe disease; drives neutrophilic inflammation and bronchial hyperresponsiveness
- rheumatoid arthritis — Synovial fluid LTB4 reaches 5-15 nM (vs <0.1 nM plasma); correlates with erosive joint damage
- inflammatory bowel disease — Mucosal LTB4 production elevated 3-10 fold in active Crohn's and ulcerative colitis driving intestinal inflammation
- Reactive Oxygen Species — LTB4 activates NADPH oxidase in neutrophils generating superoxide burst for pathogen killing but also tissue damage
- oxidative stress — LTB4-stimulated respiratory burst produces ROS causing DNA damage, lipid peroxidation, protein oxidation
- NF-kB — Transcription factor activated downstream of BLT1 driving pro-inflammatory gene expression (IL-1β, TNF-α, IL-8)
- Efferocytosis — Process of apoptotic cell clearance; impaired by excess LTB4, restored by SPMs marking resolution phase
- atherosclerosis — LTB4 recruits monocytes to arterial walls promoting foam cell formation and plaque instability
- COPD — Chronic obstructive pulmonary disease shows elevated airway LTB4 driving neutrophilic airway inflammation
- TLR4 — Pattern recognition receptor; LPS binding activates PLA2 → arachidonic acid release → LTB4 synthesis
- Calcium — Essential cofactor for 5-LOX activity; intracellular Ca²⁺ mobilization required for enzyme activation
- metabolic syndrome — Chronic low-grade inflammation with elevated LTB4 contributing to insulin resistance and adipose tissue inflammation